Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T
cells to refractory cancers but have shown limited efficacy in persistent, recurrent …
cells to refractory cancers but have shown limited efficacy in persistent, recurrent …
Chimeric antigen receptor signaling: Functional consequences and design implications
Chimeric antigen receptor (CAR) T cell therapy has transformed the care of refractory B cell
malignancies and holds tremendous promise for many aggressive tumors. Despite …
malignancies and holds tremendous promise for many aggressive tumors. Despite …
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Chimeric antigen receptor (CAR)-expressing T cells targeting surface-bound tumor antigens
have yielded promising clinical outcomes, with two CD19 CAR-T cell therapies recently …
have yielded promising clinical outcomes, with two CD19 CAR-T cell therapies recently …
Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives
YH Lee, CH Kim - Archives of pharmacal research, 2019 - Springer
Engineering T cells with a chimeric antigen receptor (CAR) that reprograms their antigen
selectivity and signaling has recently emerged as one of the most promising therapeutic …
selectivity and signaling has recently emerged as one of the most promising therapeutic …
CAR T cells in solid tumors: blueprints for building effective therapies
HM Knochelmann, AS Smith, CJ Dwyer… - Frontiers in …, 2018 - frontiersin.org
Genetic redirection of T lymphocytes with chimeric antigen receptors (CARs) has soared
from treating cancers preclinically to FDA approval for hematologic malignancies and …
from treating cancers preclinically to FDA approval for hematologic malignancies and …
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
Chimeric antigen receptor (CAR)–modified T cell therapy is effective in treating lymphomas,
leukemias, and multiple myeloma in which the tumor cells express high amounts of target …
leukemias, and multiple myeloma in which the tumor cells express high amounts of target …
Engineering CAR-T cells: design concepts
S Srivastava, SR Riddell - Trends in immunology, 2015 - cell.com
Despite being empirically designed based on a simple understanding of TCR signaling, T
cells engineered with chimeric antigen receptors (CARs) have been remarkably successful …
cells engineered with chimeric antigen receptors (CARs) have been remarkably successful …
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy
AE Firor, A Jares, Y Ma - Experimental biology and medicine, 2015 - journals.sagepub.com
In the past 50 years, disease burden has steadily shifted from infectious disease to cancer.
Standard chemotherapy has long been the mainstay of cancer medical management, and …
Standard chemotherapy has long been the mainstay of cancer medical management, and …
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Chimeric antigen receptors (CARs) are synthetic receptors that target and reprogram T cells
to acquire augmented antitumor properties. CD19-specific CARs that comprise CD28 and …
to acquire augmented antitumor properties. CD19-specific CARs that comprise CD28 and …
Fine-tuning the CAR spacer improves T-cell potency
N Watanabe, P Bajgain, S Sukumaran, S Ansari… - …, 2016 - Taylor & Francis
The adoptive transfer of genetically engineered T cells expressing chimeric antigen
receptors (CARs) has emerged as a transformative cancer therapy with curative potential …
receptors (CARs) has emerged as a transformative cancer therapy with curative potential …